Farmas USA

Cierto 😉....

para los expertos caza-mamporros:

sin news por delante que se esperen en las proximas 3 semanas ... como veis que pudiera ser el tipico comportamiento del precio tras un -85% con 50 veces el volumen medio?

En ST veo cierto optimismo (para los que quieren comprar ahora, claro), basado en el grafico de largo plazo y viendo que NVAX ya ha estado aqui otras 3-4 veces. Pero principalmente son positivos porque tiene 300 kilos en el banco, lo de la bancarrota ni se menciona (salvo por uno o dos estupidos, que siempre los hay).

El Viernes hizo un rebote intradia del +45% supongo que debido a cierre de cortos principalmente.Aunque el rebote no duro ...

El tema es que uno puede pensar en cierta recuperacion del precio tras este tremendo varapalo , $2? pero no dejo de pensar que tras 250 millones de acciones negociadas el Viernes ... 250 !! ... el precio se haya quedado SECO por unos dias ... y eso no suele traer verde ...

 

Que opinais???

 

NVAX

El volumen bestial es simplemente porque los que tenian que salir al no ver buenos resultados,,grandes capitales,, ya se han ido,quiere decir que ya no le queda mucho por abajo,,ahora entran en escena los cazarecompensas por un lado,,para sacarse un 20% o un 40%,,y los que compraran barato y acumularan a estos precios para lo que pase a medio plazo.

Nvax ni vale 9$ ni vale 1$,,,siempre hay termino medio,,despues de la tormenta calma chicha.

Total que los que la podian hundir ya lo han hecho y lo bueno es que ya no estan,,ahora????

#NVAX

Munich, Sept. 15 -- European Patent Office has released Novavax Inc's patent application for modified RSV F proteins and methods of their use. This invention was developed by Pushko Peter, Wu Yingyun, Massare Michael, Liu Ye, Smith Gale and Zhou Bin.

The patent application number is 16166033. The patent publication number is EP3067064 A1. International Patent Classification code is A61K 39/155.

According to the abstract released by the European Patent Office: "The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immuno-genic compositions such as vaccines for the treatment and/or prevention of RSV infection."

RDUS
Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR

WALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial were published in the Journal of Bone and Mineral Research (JBMR).

In the article “Effects of Abaloparatide-SC on Fracture and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors” JBMR 2016 Sept 9 [Epub ahead of print] patients in the ACTIVE trial were stratified into prespecified subgroups of baseline risk factors, inclusive of BMD, prior fracture history and age, to determine the consistency of the response for abaloparatide-SC versus placebo. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2991/epdf

“Results from the Phase 3 ACTIVE trial show that abaloparatide-SC may provide substantial benefit for a broad range of postmenopausal women with osteoporosis irrespective of their baseline risk factors, including age and prior fracture history,” said Dr. Felicia Cosman, M.D., osteoporosis specialist and Medical Director of the Clinical Research Center at Helen Hayes Hospital, Senior Clinical Director of the National Osteoporosis Foundation, Professor of Medicine at Columbia University, consultant to Radius and lead author of the paper. “These data are important for the large number of postmenopausal women who may be at risk of a fracture and show that anabolic therapy could provide more consistent, potent and early benefits and may be the most efficient way for these patients to achieve ultimate bone mineral density goals.”

“We are pleased to have these findings published in JBMR, as well as the opportunity to present additional scientific information about abaloparatide-SC as part of the American Society of Bone and Mineral Research 2016 Annual Meeting,” said Dr. Lorraine A. Fitzpatrick, Chief Medical Officer of Radius. “Approximately two million osteoporotic fractures occur annually in the U.S., which create physical and psychological burdens for those affected by diminishing their independence and quality of life. Radius Health is committed to pursuing new therapeutic options which have the potential to improve outcomes for these patients.”

Abaloparatide is an investigational treatment for postmenopausal women with osteoporosis and its safety and efficacy have not been established. A Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of patients with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA), and a New Drug Application (NDA) for abaloparatide is currently under review by the U.S. Food & Drug Administration (FDA).

About Postmenopausal Osteoporosis

Osteoporosis is a silent disease, often displaying no signs or symptoms until a fracture occurs, leaving a majority of patients undiagnosed and undertreated. Osteoporotic fractures create a significant healthcare burden, and represent a significant unmet medical need. An estimated two million osteoporotic fractures occur annually in the U.S., and this number is projected to grow to three million by 2025.

The National Osteoporosis Foundation (NOF) has estimated that 10 million people in the U.S., composed of eight million women and two million men, already have osteoporosis, and another approximately 44 million people have low bone mass placing them at increased risk for osteoporosis.

The debilitating effects of osteoporosis have substantial costs. When left untreated, osteoporosis leads to fractures which can have both physical and emotional consequences on a patient including pain and disability, inability to fully perform routine work or daily activities, and in some cases, result in death.

About ACTIVE

The Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial was a randomized, double-blind, placebo-controlled, comparative, multicenter, 18 month international study in 2,463 postmenopausal women with osteoporosis designed to evaluate the efficacy and safety of the investigational drug abaloparatide-SC 80 mcg to reduce the risk of vertebral and nonvertebral fractures. Miller PD et al, “Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis, A Randomized Clinical Trial” Journal of the American Medical Association 2016 Aug 16;316(7):722-733.

About Abaloparatide

Abaloparatide is an investigational therapy for the potential treatment of postmenopausal women with osteoporosis. Abaloparatide is a novel peptide that engages the parathyroid hormone receptor (PTH1 receptor) and was selected for clinical development based on its favorable bone building activity.

Abaloparatide has completed Phase 3 development for potential use as a daily self-administered injection (abaloparatide-SC). In the fourth quarter of 2015, Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of patients with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA). Radius submitted a New Drug Application (NDA) for abaloparatide-SC to the US Food and Drug Administration (FDA) at the end of the first quarter of 2016, which has been accepted for filing with a PDUFA date of March 30, 2017. Radius also is developing abaloparatide-transdermal (abaloparatide-TD) based on 3M's patented Microstructured Transdermal System technology for potential use as a treatment for postmenopausal women with osteoporosis.

About Radius

Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the treatment of postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review by the EMA in Europe and a New Drug Application (NDA) has been accepted for filing by the FDA with a PDUFA date of March 30, 2017. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in postmenopausal women with osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in cancer. For more information, please visit www.radiuspharm.com

¿Alguno sigue / lleva Celldex? ¿Qué opinion os merece? Últimamente he leído un par de artículos positivos, pero no lo veo claro... tiene cinco candidatos con aplicaciones múltiples, pero el pipeline parece aún muy "tierno" después de fallar un trial que tenía más avanzado en 2015.

De hecho, el mamporro acumulado que lleva desde entonces es notable...

CLDX

la verdad es que el hilo se ha vuelto 90% nvax, 10% otras farmas usa, y el culebrón sólo acaba de empezar. no sé si por aquí vendría en parte tu comentario anterior, pero sería comprensible para cualquiera que no esté por nvax.

Aquí uno intentando "diversificar"... a ver si alguien me contesta.

CLDX